Clinical Trial Update: Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Iressa (gefitinib) with best supportive care in second/third-line non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: NSCLC | Phase 3 | Status: COMPLETED